 The purpose of this study is to determine if maintenance therapy with ofatumumab will prolong remission in patients with CLL who have responded to second or third line treatment. This study will also evaluate the safety of ofatumumab maintenance compared to observation the current standard of care. This study was co-developed with the HOVON and NORDIC CLL group and will be conducted as a collaborative effort with GSK. 